Published: July 13, 2011
While Rheumatologists' Awareness and Familiarity with KRYSTEXXA Has Increased Compared to Two Months Ago, Post-Launch Metrics Including Usage Are Still Lower Compared to Analog Launches in Gout and RA
EXTON, Penn. - (BUSINESS WIRE) - BioTrends Research Group, LLC finds that, while surveyed rheumatologists
agree that KRYSTEXXA's unique mechanism of action, its ability to be
used in refractory gout patients, and its ability to break down uric
acid are its three greatest advantages, they indicate that their usage
has been hampered mainly by concerns regarding anaphylaxis or infusion
reactions, followed by its mode of administration, i.e. an infusion
every two weeks. While awareness, familiarity and ease of the managed
care process remain consistent with analog launches for Gout and
Rheumatoid Arthritis for this same time period, physician trial is below
for these same benchmarks.
Fourteen percent of the surveyed rheumatologists report that they
have initiated Savient's KRYSTEXXA (pegloticase) in at least one patient
during this second wave of the LaunchTrends:
Krystexxa report series and are relatively satisfied
with the product. Of those surveyed rheumatologists who had prescribed
KRYSTEXXA, they report that forty-five percent of their patients were
switched from either Allopurinol or Uloric (febuxostat). Overall
projections for use in the next six months are favorable.
LaunchTrends:
Krystexxa is a series of three post-launch syndicated
reports designed to track the uptake of Savient's KRYSTEXXA at one
month, three months and six months following its commercial
availability. In the current wave of research, which measures
KRYSTEXXA's market impact at three months post launch, BioTrends
surveyed 76 rheumatologists and conducted qualitative interviews with a
subset of 19 of the respondents in June 2011. BioTrends will continue to
track the uptake of KRYSTEXXA in the Wave 3 six-months post-launch
report, which will be published in September 2011, and in the ongoing TreatmentTrends:
Gout U.S. report series published twice a year and TreatmentTrends:
Gout EU published annually.
About LaunchTrends
LaunchTrends assesses trial and use of new products,
barriers to use, reasons to use, typical patient types, line of therapy,
product perceptions, promotional efforts/messages and product
satisfaction.
About BioTrends Research Group, LLC
BioTrends Research Group, LLC (www.bio-trends.com)
provides syndicated and custom market research to pharmaceutical
manufacturers competing in clinically evolving, specialty pharmaceutical
markets. For information on BioTrends publications and research
capabilities, please contact us at (610) 363-3872 or at www.bio-trends.com.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that
offers best-in-class, high-value information and insights on important
sectors of the healthcare industry. Clients rely on this analysis and
data to make informed decisions. Please visit Decision Resources, Inc.
at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be
trademarks of their respective holders.
BioTrends Research Group, LLC
Theresa Mansi, +1 610-321-9439
tmansi@bio-trends.com
or
Decision
Resources, Inc.
Christopher Comfort, +1 781-993-2597
ccomfort@dresources.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
